Charles River Laboratories International Inc. presented an update highlighting its position as a leading global partner in non-clinical drug development. The company reported a global workforce of approximately 20,000 employees, including around 2,500 scientific professionals with advanced degrees, and operates in roughly 120 locations across 20 countries. About 70% of its revenue is derived from the biopharmaceutical industry. Key business segments include Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. The RMS segment focuses on providing research models and services to support early-stage drug discovery, while the DSA segment offers outsourced drug discovery, non-clinical development, and regulated safety testing. Manufacturing Solutions accounts for quality-control testing and full-service manufacturing support. Financial highlights for the period ended September 27, 2025, include a decline in operating income margin from previous years, with GAAP operating income of $227 million and a margin of 5.6% in 2024. The company continues to emphasize operating efficiency and margin improvement, and notes positive signs in demand from small and mid-sized biotech clients. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Charles River Laboratories International Inc. published the original content used to generate this news brief on January 13, 2026, and is solely responsible for the information contained therein.
Comments